Effect of statins on biliary lipids and cholesterol gallstones

Journal fur Kardiologie

Volumn 9, Issue 7-8, 2002, Pages 295-298

  Smith, Jeffery L ^a   Riottot, M ^b   Nathanson, L K ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; CHOLERETIC AGENT; CHOLESTEROL; FLUINDOSTATIN; LIPID; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; URSODEOXYCHOLIC ACID;

ARTICLE; BILE SECRETION; CHOLESTEROL BILE LEVEL; CHOLESTEROL STONE; DRUG EFFECT; DRUG POTENTIATION; GALLSTONE DISSOLUTION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BILE LEVEL; LIPID METABOLISM; PATHOGENESIS; TREATMENT OUTCOME;

EID: 0036329911     PISSN: 10240098     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Cholesterol synthesis inhibitors in cholesterol gallstone disease
5. Plasma lipids and insulin in gall stone disease: A case-control study
6. Serum lipids and gallstones: A case-control study
7. Inverse association between plasma cholesterol and gallstone disease
8. The association between cholesterol cholelithiasis and coronary heart disease in Framingham, Massachusetts
9. Pathogenesis of cholesterol gallstones: A parsimonious hypothesis
10. Genetics and epidemiology of gallbladder disease in New World native peoples
11. Lithogenic bile in siblings of young women with cholelithiasis
12. An increased familial frequency of gallstones
13. Gallstones in a Danish population: Familial occurrence and social factors
14. Biliary lipid composition in monozygotic and dizygotic pairs of twins
15. Effects of clofibrate and of an estrogenprogestin combination on fasting biliary lipids and cholic acid kinetics in man
16. Effect of gemfibrozil on biliary lipid metabolism in normolipemic subjects
17. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenobrate
18. Bezafibrate therapy and biliary lipids: Effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia
19. Gallbladder disease as a side effect of drugs influencing lipid metabolism. Experience in the Coronary Drug Project
20. Clofibrate therapy and gallstone induction
21. Bile sampling, processing and analysis in clinical studies
22. Intestinal HMG-CoA reductase activity is low in hypercholesterolaemic patients and is further decreased with lovastatin therapy
23. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia
24. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol
25. Successful dissolution of cholesterol gallstone during treatment with pravastatin
26. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones
27. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease
28. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia
29. Effect of withdrawal of pravastatin on biliary lipid composition in humans
30. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile
31. Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in nonfamilial hypercholesterolemia
32. Changes in biliary lipid secretion and cholic acid kinetics induced by diet, diet plus simvastatin and diet plus ursodeoxycholic acid in obese subjects
33. Cholesterol metabolism and serum and biliary noncholesterol sterols in gallstone patients during simvastatin and ursodeoxycholic acid treatments
34. Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor
35. Effect of long term simvastatin administration as an adjunct to ursodeoxycholic acid: Evidence for a synergistic effect on biliary bile acid composition but not on serum lipids in humans
36. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones
37. Effect of simvastatin on hepatic and gallbladder bile lithogenicity and bile acid hydrophobicity in patients with confirmed cholesterol gallstones
38. Effects of fluvastatin on human biliary lipids
39. Effects of Fluvastatín on biliary lipids in subjects with elevated cholesterol saturation index
40. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia
41. Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans
42. Effects of lovastatin and dietary cholesterol on sterol homeostasis in healthy human subjects
43. Simvastatin and ursodeoxycholic acid for rapid gallstone dissolution
44. A combination therapy with simvastatin and ursodeoxycholic acid is more effective for cholesterol gallstone dissolution than is ursodeoxycholic acid monotherapy